Drugs for Ventricular Septal Defect (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 58)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Salbutamol |
Approved, Vet_approved |
Phase 4 |
|
18559-94-9 |
2083 |
Synonyms:
(±)-SALBUTAMOL
(L)-Albuterol
1-(Tert-butylaminomethyl)-4-hydroxy-m-xylene-alpha1,alpha3-diol
2-(Tert-butylamino)-1-(4-hydroxy-3-hydroxymethylphenyl)ethanol
2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol
4-Hydroxy-3-hydroxymethyl-alpha-((tert-butylamino)methyl)benzyl alcohol
ACCUNEB
Aerolin
AEROLIN 400
AEROLIN AUTO
AIROMIR
AIRSALB
Albuterol
Albuterol sulfate
Albuterol Sulphate
albuterol|SCH-13949W|Ventolin®
Almotex
Alpha'-((tert-butylamino)methyl)-4-hydroxy-m-xylene-alpha,alpha'-diol
Alti-salbutamol
Anebron
Arubendol-salbutamol
Asmadil
Asmanil
Asmasal
ASMASAL CLICKHALER
ASMASAL SPACEHALER
Asmatol
Asmaven
ASMAVENT
Asmidon
Asmol
Asmol uni-dose
Asthalin
Asthavent
Broncho-spray
Broncovaleas
Bronter
BTA204
Bugonol
Bumol
Butamol
Buto-asma
Butohaler
Butotal
Butovent
Buventol
Cetsim
Cobutolin
COMBIVENT
COMBIVENT UDVS
Dilatamol
DL-Albuterol
DL-N-Tert-butyl-2-(4-hydroxy-3-hydroxymethylphenyl)-2-hydroxyethylamine
DL-Salbutamol
DUONEB
Ecovent
Farcolin
Gerivent
Grafalin
IPRAMOL STERI-NEB
KENTAMOL
Levalbuterol
LIBETIST
Libretin
Loftan
MAXIVENT
Medolin
Mozal
Novosalmol
Parasma
Pneumolat
ProAir
PROAIR HFA
Proventil
|
Proventil hfa
Proventil inhaler
PROVENTIL-HFA
Respax
Respolin
RIMASAL
Rotahaler
R-Salbutamol
Sabutal
Salamol
SALAMOL E-BREATHE
SALAPIN
Salbetol
Salbron
Salbu-basf
Salbu-fatol
Salbuhexal
Salbulin
SALBULIN NOVOLIZER
Salbupur
Salbusian
Salbutalan
SALBUTAMOL
Salbutamol free base
Salbutamol sulfate
Salbutamol sulphate
Salbutamolum
Salbutan
Salbutard
Salbutine
Salbutol
Salbuven
Salbuvent
SALIPRANEB
Sallbupp
Salmaplon
Salomol
Salvent
Saventol
SCH 13949W
SCH-13949W
Servitamol
Solbutamol
Spreor
STERI-NEB SALAMOL
Sultanol
Sultanol N
Suprasma
Suxar
Theosal
Tobybron
Vencronyl
Venetlin
Ventalin Inhaler
Ventamol
Ventilan
Ventiloboi
VENTMAX SR
Ventodisks
Ventolin
VENTOLIN CR
VENTOLIN E-BREATHE
VENTOLIN HFA
Ventolin inhaler
Ventolin rotacaps
Ventoline
Volare albuterol hfa
Volare easi-breathe
Volma
Volmax
Xopenex
Xopenex HFA
Zaperin
|
|
2 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
3 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
4 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
5 |
|
Bronchodilator Agents |
|
Phase 4 |
|
|
|
6 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
7 |
|
Anti-Asthmatic Agents |
|
Phase 4 |
|
|
|
8 |
|
Respiratory System Agents |
|
Phase 4 |
|
|
|
9 |
|
Tocolytic Agents |
|
Phase 4 |
|
|
|
10 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
1994-09-7, 94-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-Aminobenzoic acid ethyl ester
4-Carbethoxyaniline
Acetate, benzocaine
Aethoform
AEZODENT
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthin
Anestezin
Anesthesin
Anesthesine
Anesthone
ANTHISAN PLUS
AR01
AR-01
Baby anbesol
Bensokain
Benzoak
Benzocaina
BENZOCAINE
Benzocaine acetate
Benzocaine formate
Benzocaine hydrobromide
Benzocaine hydrochloride
Benzocaine methanesulfonate
Benzocainum
BURNEZE
CHILDREN'S CHLORASEPTIC
DEQUACAINE
Dermoplast
Diet ayds
Ethoform
Ethyl 4-aminobenzoate
|
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoic acid
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-aminophenylcarboxylic acid
Ethylester kyseliny P-aminobenzoove
Formate, benzocaine
Hurricaine
Hydrobromide, benzocaine
Hydrochloride, benzocaine
Identhesin
Keloform
LANACANE
MEDILAVE
Methanesulfonate, benzocaine
NESTOSYL
Norcain
Norcaine
NSC-41531
NSC-4688
Orabase-b
Ora-jel
ORAJEL
Orthesin
p-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
P-Aminobenzoic acid ethyl ester
Parathesin
Parathesine
p-Carbethoxyaniline
p-Ethoxycarboxylic aniline
Slim mint gum
Solarcaine
Solu H
Topcaine
TYROSOLVEN
TYROZETS
|
|
11 |
|
Tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
16129878 16129778 |
Synonyms:
Acid, tannic
ácido tánico
Acids, tannic
E181
FEMA NO. 3042
Gallotannic acid
|
Gallotannin
NSC-656273
TANNIC ACID
Tannic acids
Tannins
|
|
12 |
|
Enalaprilat |
Approved |
Phase 3 |
|
76420-72-9 |
6917719 5462501 |
Synonyms:
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline dihydrate
Anhydrous enalaprilat citrate
Anhydrous, enalaprilat
Biovail brand OF enalaprilat anhydrous
Boehringer ingelheim brand OF enalaprilat anhydrous
Dihydrate, enalaprilat
Enalapril acid
Enalapril diacid
Enalapril teva
ENALAPRILAT
Enalaprilat anhydrous
Enalaprilat citrate, anhydrous
Enalaprilat dihydrate
Enalaprilat, (R)-isomer, anhydrous
|
Enalaprilate
Enalaprilatum
Enalaprilic acid
Enalapril-teva
EnalaprilTEVA
Merck frosst brand OF enalaprilat anhydrous
MK-421
MK-422
MSD Brand OF enalaprilat
N-[(1S)-1-Carboxy-3-phenylpropyl]-L-alanyl-L-proline
Pres IV
Teva brand OF enalaprilat
Vasotec
Xanef
|
|
13 |
|
Enalapril |
Approved, Vet_approved |
Phase 3 |
|
75847-73-3 |
40466924 5388962 5362032 |
Synonyms:
(S)-1-(N-(1-(Ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylate
(S)-1-{(S)-2-[1-((S)-ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid
1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester
Analapril
ánalapril
Bonuten
C09AA02
ENALADEX
Enaladex®|Vasotec®
Enalapril
Enalapril Bp
Enalapril maleate
Enalapril Richet
Enalaprila
|
Enalaprila [INN-Spanish]
Enalaprilat
Enalaprilum
Enalaprilum [INN-Latin]
EPL753
Gadopril
Kinfil
LEXXEL
Maleate, enalapril
Renitec
Renitek
VASERETIC
VASOTEC
Vasotec IV
|
|
14 |
|
Plasma-lyte 148 |
|
Phase 3 |
|
|
|
15 |
|
Ophthalmic Solutions |
|
Phase 3 |
|
|
|
16 |
|
Antihypertensive Agents |
|
Phase 3 |
|
|
|
17 |
|
Angiotensin-Converting Enzyme Inhibitors |
|
Phase 3 |
|
|
|
18 |
|
HIV Protease Inhibitors |
|
Phase 3 |
|
|
|
19 |
|
protease inhibitors |
|
Phase 3 |
|
|
|
Synonyms:
|
20 |
|
Sodium citrate |
Approved, Investigational |
Phase 1, Phase 2 |
|
68-04-2 |
23431961 |
Synonyms:
Anhydrous sodium citrate
Anhydrous trisodium citrate
Citric acid, trisodium salt
Natrii citras
Natrocitral
Sodium citrate anhydrous
Sodium citrate, anhydrous
|
Sodium citrate,anhydrous
Sodium citric acid
Trisodium 2-hydroxypropane-1,2,3-tricarboxylate
trisodium citrate anhydrous
Trisodium citrate, anhydrous
Trisodium-citrate
|
|
21 |
|
Sildenafil |
Approved, Investigational |
Phase 1, Phase 2 |
|
139755-83-2, 171599-83-0 |
5212 135398744 |
Synonyms:
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine
1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulphonyl)-4-methylpiperazine
1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate
1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
Acetildenafil
Aphrodil
Caverta
Citrate, sildenafil
Desmethyl sildenafil
Desmethylsildenafil
HIP0908
HIP-0908
Homosildenafil
Hydroxyhomosildenafil
Lactate, sildenafil
NCX 911
|
NCX-911
NIPATRA
Nitrate, sildenafil
Revatio
Sildenafil
Sildenafil citrate
Sildenafil lactate
Sildenafil nitrate
Sildenafil Viagra
Sildenafil, desmethyl
Sildenafilo
UK-92480
UK-9248010
UK-92480-10
Viagra
Viagra®
VIZARSIN
|
|
22 |
|
Milrinone |
Approved |
Phase 1, Phase 2 |
|
78415-72-2 |
4197 |
Synonyms:
1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile
Corotrop
Corotrope
Lactate, milrinone
Milrila
Milrinona
Milrinone
Milrinone lactate
milrinone lactate|Primacor®
|
Milrinonum
Primacor
Sanofi brand OF milrinone lactate
Sanofi synthelabo brand OF milrinone
Sanofi synthelabo brand OF milrinone lactate
Sanofi winthrop brand OF milrinone lactate
WIN-472032
WIN-47203-2
|
|
23 |
|
Dexmedetomidine |
Approved, Experimental, Vet_approved |
Phase 2 |
|
86347-14-0, 113775-47-6 |
68602 5311068 |
Synonyms:
(+)-4-((S)-a,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole
(+)-4-((S)-Α,2,3-trimethylbenzyl)imidazole
(+-)-4-(a,2,3-Trimethylbenzyl)imidazole
(+-)-4-(alpha,2,3-Trimethylbenzyl)imidazole
(+-)-4-(Α,2,3-trimethylbenzyl)imidazole
(+)-MEDETOMIDINE
(±)-4-(α,2,3-trimethylbenzyl)imidazole
(S)-MEDETOMIDINE
Dexdor
Dexdor®|Igalmi® (dexmedetomidine sublingual film)|MPV 1440|Precedex®
DEXMEDETOMIDIN
Dexmedetomidina
DEXMEDETOMIDINE
DEXMÉDÉTOMIDINE
Dexmedetomidine hydrochloride
Dexmedetomidinum
|
Domitor
Hospira brand OF dexmedetomidine hydrochloride
Hydrochloride, dexmedetomidine
Hydrochloride, medetomidine
Levomedetomidine
Medetomidina
Medetomidina [Spanish]
Medetomidine
Medetomidine hydrochloride
Medetomidinum
Medetomidinum [Latin]
MPV 1440
MPV 785
MPV-1440
MPV-785
Precedex
|
|
24 |
|
Ketamine |
Approved, Vet_approved |
Phase 2 |
|
6740-88-1, 1867-66-9 |
3821 |
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
Calipsol
Calypsol
CI 581 base
CLSTA 20
DL-Ketamine
Esketamine
Kalipsol
Ketaject
Ketalar
|
Ketalar base
Ketalar|ketamine HCl
Ketamina
KETAMINE
Kétamine
Ketamine base
Ketamine HCL
Ketamine hydrochloride
Ketaminum
Ketanest
Ketaset
Ketolar
L-Ketamine
NMDA
NSC-70151
Special K
Tekam
|
|
25 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 2 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
ABSTRAL
Abstral®|Actiq®|Durogesic®|Effentora®|MCN-JR-4263-49|R-4263|Sublimaze®
ACTIQ
AD 923
AD-923
BREAKYL
Cephalon brand OF fentanyl buccal oravescent
Duragesic
DURAGESIC-100
DURAGESIC-12
DURAGESIC-25
DURAGESIC-37
DURAGESIC-50
DURAGESIC-75
Durogesic
DUROGESIC DTRANS
EFFENTORA
FENCINO
FENTALIS RESERVOIR
Fentanest
Fentanil
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl CII
Fentanyl citrate
FENTANYL-100
FENTANYL-12
FENTANYL-25
FENTANYL-37
FENTANYL-50
FENTANYL-62
FENTANYL-75
FENTANYL-87
Fentanylum
|
Fentanylum [INN-Latin]
Fentora
IDS-NF-001
INNOVAR
IONSYS
Janssen pharmaceutica brand OF fentanyl
LEPTANAL
MATRIFEN
MCN-JR-4263-49
MEZOLAR MATRIX
MYLAFENT
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N02AB03
Nasalfent
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
OPIODUR
ORALET
OSMACH
OSMANIL
PECFENT
Pentanyl
Phentanyl
R 4263
R-4263
Rapinyl
RECIVIT
Sentonil
Sublimaze
Subsys
TILOFYL
Transmucosal oral fentanyl citrate
VICTANYL
YEMEX
|
|
26 |
|
Citric acid |
Approved, Nutraceutical, Vet_approved |
Phase 1, Phase 2 |
|
77-92-9 |
311 |
Synonyms:
2-hydroxy-1,2,3-propanetricarboxyic acid
2-Hydroxy-1,2,3-propanetricarboxylate
2-Hydroxy-1,2,3-propanetricarboxylic acid
2-Hydroxytricarballylate
2-Hydroxytricarballylic acid
3-Carboxy-3-hydroxypentane-1,5-dioate
3-Carboxy-3-hydroxypentane-1,5-dioic acid
Acid monohydrate, citric
ácido cítrico
Acidum citricum
Aciletten
Anhydrous citrate
Anhydrous citric acid
beta-Hydroxytricarballylate
beta-Hydroxytricarballylic acid
Chemfill
Citraclean
Citrate
Citrate anhydrous
Citretten
CITRIC ACID
Citric acid anhydrous
CITRIC ACID HYDRATE
Citric acid monoglyceride
|
Citric acid monohydrate
Citric acid, anhydrous
Citric acid,anhydrous
Citro
Citronensaeure
Citronensäure
e 330
e330
E-330
FEMA NO. 2306
H3Cit
Hydrocerol a
INS NO.330
INS-330
Kyselina citronova
Monohydrate, citric acid
NSC-112226
NSC-30279
NSC-626579
Suby g
Uralyt u
UROLOGIC G
Uro-trainer
|
|
27 |
|
Anesthetics |
|
Phase 2 |
|
|
|
28 |
|
Cardiotonic Agents |
|
Phase 1, Phase 2 |
|
|
|
29 |
|
Phosphodiesterase Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
30 |
|
Phosphodiesterase 5 Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
31 |
|
Phosphodiesterase 3 Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
32 |
|
Vasodilator Agents |
|
Phase 1, Phase 2 |
|
|
|
33 |
|
Platelet Aggregation Inhibitors |
|
Phase 1, Phase 2 |
|
|
|
34 |
|
Citrate |
|
Phase 1, Phase 2 |
|
|
|
35 |
|
Protective Agents |
|
Phase 1, Phase 2 |
|
|
|
36 |
|
Adrenergic alpha-Agonists |
|
Phase 2 |
|
|
|
37 |
|
Hypnotics and Sedatives |
|
Phase 2 |
|
|
|
38 |
|
Analgesics, Non-Narcotic |
|
Phase 2 |
|
|
|
39 |
|
Analgesics |
|
Phase 2 |
|
|
|
40 |
|
Excitatory Amino Acid Antagonists |
|
Phase 2 |
|
|
|
41 |
|
Anesthetics, Intravenous |
|
Phase 2 |
|
|
|
42 |
|
Anesthetics, General |
|
Phase 2 |
|
|
|
43 |
|
Anesthetics, Dissociative |
|
Phase 2 |
|
|
|
44 |
|
Calcium, Dietary |
|
Phase 2 |
|
|
|
45 |
|
Anticoagulants |
|
Phase 2 |
|
|
|
46 |
|
Analgesics, Opioid |
|
Phase 2 |
|
|
|
47 |
|
Narcotics |
|
Phase 2 |
|
|
|
48 |
|
Chelating Agents |
|
Phase 2 |
|
|
|
49 |
|
Blood Substitutes |
|
Phase 2 |
|
|
|
50 |
|
Plasma Substitutes |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 48)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial |
Completed |
NCT02914652 |
Phase 4 |
Salbutamol;Norflouran (Placebo Evohaler(R) ) |
2 |
A Randomized Controlled Trial of Minimally Invasive Transthoracic Device Closure in the Treatment of Patients With Perimembranous Ventricular Septal Defect |
Unknown status |
NCT02644330 |
Phase 2, Phase 3 |
|
3 |
Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest |
Completed |
NCT00000470 |
Phase 3 |
|
4 |
A Phase III Double-Blind, Randomized, Placebo Controlled, Multi Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects |
Recruiting |
NCT05253209 |
Phase 3 |
L-citrulline;Plasmalyte A |
5 |
Trial of ACE Inhibition in Children With Mitral Regurgitation After Repair of AVSD |
Terminated |
NCT00113698 |
Phase 3 |
Enalapril |
6 |
Effects of Adding Oral Sildenafil to Intravenous Milrinone on Postoperative Pulmonary Hypertension in Pediatric Undergoing Repair of Ventricular Septal Defect |
Completed |
NCT02595541 |
Phase 1, Phase 2 |
milrinone;Sildenafil |
7 |
Use of Ketamine Prior to Cardiopulmonary Bypass in Children |
Completed |
NCT00556361 |
Phase 2 |
saline;ketamine |
8 |
Phase IB Double Blind, Randomized, Placebo Controlled Clinical Trial to Determine the Pharmacokinetics and Safety of a Revised Protocol of Intravenous L-Citrulline (Citrupress®) Versus Placebo in Children Undergoing Cardiopulmonary Bypass |
Completed |
NCT01120964 |
Phase 1, Phase 2 |
Intravenous L-Citrulline;Placebo of Intravenous L-Citrulline |
9 |
Stress Response in Children Undergoing Cardiac Surgery: a Prospective Randomized Comparison Between Low Dose Fentanyl (LDF), Low Dose Fentanyl Plus Dexmedetomidine (LDF + Dex) and High Dose Fentanyl (HDF). |
Completed |
NCT00848393 |
Phase 2 |
Fentanyl (High Dose);Fentanyl (Low Dose);Fentanyl (Low Dose) + Dexmedetomidine |
10 |
The Use of Hypertonic Saline Dextran in Cardiac Surgery Utilizing Cardio Pulmonary Bypass in Children Less Than 17 Weeks Old. |
Completed |
NCT00199771 |
Phase 2 |
7.5% NaCl in 6% dextran 70 solution |
11 |
Optical Tissue Identification for Myocardial Architecture (OPTIMA Study) |
Active, not recruiting |
NCT04017975 |
Phase 2 |
Fluorescite |
12 |
A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics |
Completed |
NCT01915277 |
Phase 1 |
Dexmedetomidine |
13 |
Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER |
Completed |
NCT00578708 |
Phase 1 |
|
14 |
Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow |
Withdrawn |
NCT01825369 |
Phase 1 |
IV L-carnitine |
15 |
Aortic Regurgitation After Surgical Repair of Outlet-Type Ventricular Septal Defect |
Unknown status |
NCT00173186 |
|
|
16 |
Changes in Ventricular Remodeling and Exercise Cardiopulmonary Function After Transcatheter Closure of Ventricular Septal Defect |
Unknown status |
NCT03127748 |
|
|
17 |
Chinese Academy of Medical Sciences, Fuwai Hospital |
Unknown status |
NCT03941691 |
|
|
18 |
Study of Energy Expenditure in Infants With Ventricular Septal Defects |
Unknown status |
NCT00006272 |
|
|
19 |
Ad Hoc Analysis for the Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With a Closed Ventricular Septal Defect |
Completed |
NCT02648984 |
|
|
20 |
Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect |
Completed |
NCT03684161 |
|
|
21 |
Cardiac Output During Exercise in Young Adults Operated for Ventricular Septal Defect as Children |
Completed |
NCT02138435 |
|
|
22 |
Transcatheter Versus Surgical Closure of Ventricular Septal Defect: A Comparative Study |
Completed |
NCT05306483 |
|
|
23 |
The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters |
Completed |
NCT04859036 |
|
|
24 |
The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension |
Completed |
NCT01313832 |
|
|
25 |
Femoral Allogenic Vein Valved Conduit for Palliative Repair of Pulmonary Atresia With Ventricular Septal Defect |
Completed |
NCT02861963 |
|
|
26 |
Postoperative Right Bundle Branch Block - Long-term Effect on the Right Ventricle in Children Operated for Ventricular Septal Defect |
Completed |
NCT01480908 |
|
|
27 |
Mechanical Complications of Acute Myocardial Infarction: an International Multicenter Cohort Study (CAUTION Study 1) |
Completed |
NCT03848429 |
|
|
28 |
The AMPLATZERâ„¢ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study |
Completed |
NCT03165526 |
|
|
29 |
Nutritional, Hormonal and Anthropometric Evaluation of Children After Transcatheter VSD Closure |
Completed |
NCT05200910 |
|
|
30 |
TEE-guided Perventricular Device Closure Through Minithoracotomy vs Traditional Surgery Repair Via CBP in Treatment of Infundibular Ventricular Septal Defect:A Two-center Clinical Randomized Controlled Trial |
Completed |
NCT02361008 |
|
|
31 |
Prospective, Monocentric Study for the Evaluation of Latent Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions Lost to Follow-up. |
Completed |
NCT02552485 |
|
|
32 |
Precision Assessment of Perioperative Effectiveness and Safety of Transthoracic Minimally Invasive Hybrid Closure for Pediatric Ventricular Septal Defects |
Completed |
NCT02794584 |
|
sufentanil anesthesia |
33 |
Clinical Evaluation of Transcatheter Closure and Surgery of Perimembranous Ventricular Septal Defects |
Completed |
NCT00890799 |
|
|
34 |
Closure of Muscular Ventricular Septal Defects With The AMPLATZERâ„¢ Muscular VSD Occluder |
Completed |
NCT00583791 |
|
|
35 |
International Multicentre Clinical Device Investigation on Safety and Effectiveness of the Nit-Occlud® Lê VSD Spiral Coil System for VSD Occlusion Developed by Pfm AG, Cologne |
Completed |
NCT00390702 |
|
|
36 |
Molecular Genetic Epidemiology of Three Cardiac Defects -SCOR in Pediatric Cardiovascular Disease |
Completed |
NCT00005546 |
|
|
37 |
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease |
Completed |
NCT00005322 |
|
|
38 |
Reproduction and Survival After Cardiac Defect Repair |
Completed |
NCT00005190 |
|
|
39 |
Targeting Normoxia in Neonates With Cyanotic Congenital Heart Disease in the Intra-operative and Immediate Post-operative Period (T-NOX) |
Recruiting |
NCT04452188 |
|
|
40 |
Amplatzerâ„¢ Trevisioâ„¢ Delivery System Post-Approval Study |
Recruiting |
NCT04433520 |
|
|
41 |
A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® Perimembranous Ventricular Septal Defect (PmVSD) Occluder in Patients With Perimembranous Ventricular Septal Defects |
Recruiting |
NCT04034498 |
|
|
42 |
Lifetech KONAR-MFâ„¢ VSD Occluder Post-Market Clinical Follow-Up Study Clinical Investigation Plan |
Recruiting |
NCT04417712 |
|
|
43 |
French Observatory of Congenital Ventricular Septal Defect With Pulmonary Overload |
Active, not recruiting |
NCT03363932 |
|
|
44 |
A Multicenter, International, Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® Muscular Ventricular Septal Defect (mVSD) Occluder in Patients With Muscular Ventricular Septal Defects |
Active, not recruiting |
NCT05329350 |
|
|
45 |
Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder - Post Approval Study |
Active, not recruiting |
NCT00647387 |
|
|
46 |
Improving Care for Children With Congenital Heart Disease by Cardiovascular Biomarker Profiling and Advanced Non-invasive Cardiac Imaging Techniques. |
Enrolling by invitation |
NCT04667455 |
|
|
47 |
Optimal Timing for Repair of Left-to-Right Shunt Lesions |
Terminated |
NCT00229827 |
|
|
48 |
Rhythm Disturbances After Ventricular Septal Defects |
Terminated |
NCT00208624 |
|
|
|